Viewing Study NCT06106802


Ignite Creation Date: 2025-12-25 @ 3:57 AM
Ignite Modification Date: 2026-04-13 @ 3:54 PM
Study NCT ID: NCT06106802
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-10-30
First Post: 2023-10-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Sponsor: Samsung Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module